SLPI as a dedifferentiation biomarker in BRAFV600E-mutant papillary thyroid cancer
Abstract The BRAFV600E mutation drives papillary thyroid carcinoma (PTC) progression and therapy resistance, yet its downstream effectors remain incompletely characterized. Here, we identify secretory leukocyte protease inhibitor (SLPI) as a novel dedifferentiation biomarker in BRAFV600E-mutant PTC through integrated multi-omics analyses and functional validation. SLPI expression was significantly elevated in BRAFV600E-mutant tumors and correlated with advanced TNM stage, lymph node metastasis, and poor survival. Its overexpression was caused mechanistically by AP-1 transactivation and SLPI promoter hypomethylation. SLPI knockdown in PTC cells
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in